The manufacturer of zafirlukast (Accolate®) has discontinued this product with effect from the end of March 2018. No further supplies are being made and it is predicted that minimal supplies will be available within the supply chain.
Commercial reasons are cited for this decision and it is stressed that there were no safety concerns with this medicine. Zafirlukast is a leukotriene receptor antagonist and as such the closest available alternative is montelukast.
Action: Clinicians should be aware of this product being discontinued. It would be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow a review and arrangements made to identify a suitable alternative.
|« SMC Update - April 2018||NICE Guidance - April 2018 »|